“…Along with cervical cancer, HPV types 16 and 18 are responsible for 40%-50% of invasive vulvar cancer and 70% of vaginal cancer [3]. 18,31,33,35,39,45,51,52,56,58,59, 66, 68, 73 and 82 are considered high risk genotypes, whereas low-risk genotypes include HPV- 6,11,34,40,42,43,44,54,61,70,72,81, and 89 [4]. There are three available HPV vaccines licensed by the U.S. Food and Drug Administration (FDA): quadrivalent HPV vaccine, including HPV types 6,11,16 and 18 (Gardasil®, produced by Merck); bivalent HPV vaccine, including HPV types 16 and 18 (Cervarix™, produced by GlaxoSmithKline), and nine-valent vaccine, including HPV types 6,11,16,18,31,33,45,52 and 58 (Gardasil 9; produced by Merck) [5,6].…”